Tumor-infiltrating plasma cells are key responders to immunotherapy. In this issue of Cancer Cell, Meyerhoff et al. show that plasma cells from lung lesions of anti-PD-1-treated patients target citrullinated proteins. Engineering CAR T cells with these plasma cells scFv reveals anti-tumor specificity without adverse effects, identifying therapeutic opportunities.
Related products
| Catalog No. | Product Name | Description | Target |
|---|---|---|---|
| HX959021 | Recombinant Human CD269/TNFRSF17/BCMA Protein | Recombinant Human CD269/TNFRSF17/BCMA Protein, C-Fc (HX959021) expressed in Mammalian Cells, spanning Leu2-Ala54. Purity: >90% by SDS-PAGE. Highlights ●Fc Fusion — Enhanced stability with Protein A/G purification compatibility. ●Mammalian Expression — Proper folding and native glycosylation. ●High Purity — >90% purity verified by SDS-PAGE. |
+86-27-87433958
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский